1-(3-溴丙基)-4-乙基苯 | 181805-79-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴丙基)-4-乙基苯
• 英文名称: 1-(3-bromopropyl)-4-ethylbenzene
• 英文别名: 4-(3-bromopropyl)-1-ethylbenzene
• CAS: 181805-79-8
• 化学式: C₁₁H₁₅Br
• 分子量: 227.144
• InChiKey: CNJHQKKMASTTAY-UHFFFAOYSA-N

物化性质

• 沸点：
  259.6±9.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙基)-4-乙基苯 、 {2,2-dimethyl-5-[2-(4-hydroxy-3-trifluoromethylphenyl)ethyl]-1,3-dioxan-5-yl}carbamic acid t-butyl ester 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 [5-(2-{4-[3-(4-ethylphenyl)propoxy]-3-trifluoromethylphenyl}ethyl)-2,2-dimethyl-1,3-dioxan-5-yl]carbamic acid t-butyl ester
  参考文献：
  名称：

  AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  公开号：

  EP2168944B1
• 作为产物：
  描述：

  3-(4-乙基苯基)-1-丙醇 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-(3-溴丙基)-4-乙基苯
  参考文献：
  名称：

  AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  公开号：

  EP2168944B1

文献信息

• Silacyclohexane compounds, preparation thereof, liquid crystal
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US05665271A1

  公开（公告）日：1997-09-09

  Silacyclohexane compounds of the following formula (I) or (II) along with intermediate compounds therefor are described ##STR1## wherein R is an organic residue, one of ##STR2## represents a trans-1-sila-1,4-cyclohexylene group or trans-4-sila-1,4-cyclohexylene group having a substituent of H, F, Cl or CH.sub.3, and the other represents a trans-1,4-cyclohexylene group, or such a trans-1-sila-1,4-cyclohexylene group or trans-4-sila-1,4-cyclohexylene group as defined above, n is 0 or 1, L.sub.1 represents H or F, L.sub.2 represents H, F or Cl, and Z represents CN, F, Cl or an organic residue, and ##STR3## The processes for preparing the compounds (I) and (II) are also described along with liquid crystal compositions comprising the compounds and the liquid crystal devices comprising the compositions.

  以下是化学方程式的中文翻译： 描述了具有以下化学式（I）或（II）的硅环己烷化合物以及其中间体化合物##STR1##其中R是有机残基，##STR2##中的一个代表具有H、F、Cl或CH.sub.3取代基的反式-1-硅-1,4-环己烯基或反式-4-硅-1,4-环己烯基，另一个代表反式-1,4-环己烯基，或者如上定义的反式-1-硅-1,4-环己烯基或反式-4-硅-1,4-环己烯基，n为0或1，L.sub.1代表H或F，L.sub.2代表H、F或Cl，Z代表CN、F、Cl或有机残基，以及##STR3##还描述了制备化合物（I）和（II）的过程，以及包括这些化合物的液晶组合物和包括这些组合物的液晶器件。
• Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization
  作者：Jee Sun Yang、Chulho Lee、Misun Cho、Hyuntae Kim、Jae Hyun Kim、Seonghwi Choi、Soo Jin Oh、Jong Soon Kang、Jin-Hyun Jeong、Hyun-Jung Kim、Gyoonhee Han

  DOI：10.1021/acs.jmedchem.5b00062

  日期：2015.4.23

  a novel strategy for anticancer chemotherapy by restoring runt-related transcription factor 3 (RUNX3) levels via lactam-based histone deacetylase (HDAC) inhibitors that stabilize RUNX3. Described here are the synthesis, biological evaluation, and pharmacokinetic evaluation of new synthetic small molecules based on pyridone-based HDAC inhibitors that specifically stabilize RUNX3 by acetylation and regulate

  最近，我们通过稳定内含RUNX3的内酰胺基组蛋白脱乙酰基酶（HDAC）抑制剂，恢复了矮子相关转录因子3（RUNX3）的水平，从而确定了一种抗癌化学疗法的新策略。在此描述的是基于吡啶酮的HDAC抑制剂的新型合成小分子的合成，生物学评估和药代动力学评估，这些小分子通过乙酰化作用专门稳定RUNX3并调节其功能。许多新合成的化合物显示出良好的RUNX活性，HDAC抑制活性和对人类癌细胞系生长的抑制活性。值得注意的是，这些新衍生物之一是（E）-N-羟基-3-（2-氧代-1-（喹啉-2-基甲基）-1,2-二氢吡啶-3-基）丙烯酰胺（4l），以剂量依赖的方式显着恢复RUNX3，并显示出高代谢稳定性，良好的药代动力学特征，高口服生物利用度和长半衰期以及强大的抗肿瘤活性。这项研究表明，基于吡啶酮的类似物可通过表观遗传调控以及RUNX3的强转录和翻译后调控来调控RUNX3活性，并且可能作为口服可用的RUNX3
• Amine compound and pharmaceutical use thereof
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08129361B2

  公开（公告）日：2012-03-06

  Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

  提供的是一种新型胺类化合物，其化学式如下（I），具有卓越的外周血淋巴细胞降低作用和免疫抑制作用，抗排异作用等方面表现出降低副作用的优点，例如心动过缓等，或其药学上可接受的酸盐，或其水合物，或其溶剂化物。 其中，每个符号如规范中所定义。
• Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0637580A1

  公开（公告）日：1995-02-08

  A 1-bromoalkylbenzene derivative is prepared by reacting a phenylalkene derivative with hydrogen bromide in the presence of a non-polar solvent. The phenylalkene derivative is prepared by reacting an alkenyl halide with metal magnesium to form a Grignard reagent, and then reacting the Grignard reagent with a benzyl halide derivative. An allyl Grignard reagent is prepared by reacting continuously an allyl halide derivative with metal magnesium in an organic solvent, in which the allyl halide derivative and metal magnesium are continuously added to the reaction system and the allyl Grignard reagent formed is continuously removed from the reaction system. The processes provide the intended compounds in high yields, high selectivities and high purities.

  1-bromoalkylbenzene derivative is prepared by reacting a phenylalkene derivative with hydrogen bromide in the presence of a non-polar solvent.苯基烷烃衍生物的制备方法是先使烯基卤化物与金属镁反应生成格氏试剂，然后使格氏试剂与苄基卤化物衍生物反应。烯丙基格氏试剂是通过烯丙基卤化物衍生物与金属镁在有机溶剂中连续反应制备的，其中烯丙基卤化物衍生物和金属镁被连续加入反应体系，形成的烯丙基格氏试剂被连续从反应体系中移除。这些工艺可提供高产率、高选择性和高纯度的预期化合物。
• Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：EP0727428A1

  公开（公告）日：1996-08-21

  The invention relates to a silacyclohexane compound of the following formula (I) or (II) which is useful as a liquid crystal wherein R is an organic residue, one of which may be the same or different, is a trans-1-sila-1,4-cyclohexylene or trans-4-sila-1,4-cyclohexylene group which is substituted on the silicon atom by H, F, Cl or CH3, and the other is a trans-1,4-cyclohexylene group, or a trans-1-sila-1,4-cyclohexylene or trans-4-sila-1,4-cyclohexylene group as defined above, n is 0 or 1, L1 is H or F, L2 is H, F or Cl, and Z is CN, F, Cl or an organic residue. Processes for producing the compounds (I) and (II) are described, along with liquid crystal compositions comprising the compounds and liquid crystal devices comprising the compositions.

  本发明涉及一种可用作液晶的下式（I）或（II）的硅环己烷化合物 其中 R 是有机残留物、 其中之一 其中一个可以相同或不同，是硅原子上被 H、F、Cl 或 CH3 取代的反式-1-硅杂-1,4-环己烯或反式-4-硅杂-1,4-环己烯基团，另一个是反式-1、4-环己烯基团，或如上定义的反式-1-西拉-1,4-环己烯或反式-4-西拉-1,4-环己烯基团，n 为 0 或 1，L1 为 H 或 F，L2 为 H、F 或 Cl，Z 为 CN、F、Cl 或有机残基。 本文介绍了化合物（I）和（II）的生产工艺，以及包含这些化合物的液晶组合物和包含这些组合物的液晶器件。